AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED As OF ____________ BOLT BIOTHERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENTWarrant Agreement • March 30th, 2022 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between BOLT BIOTHERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
•] Shares BOLT BIOTHERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.00001 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • February 1st, 2021 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations • New York
BOLT BIOTHERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF BOLT BIOTHERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENTWarrant Agreement • March 30th, 2022 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations • New York
THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between BOLT BIOTHERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
BOLT BIOTHERAPEUTICS, INC. COMMON STOCK SALES AGREEMENTSales Agreement • March 30th, 2022 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations • New York
Bolt Biotherapeutics, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
WARRANT TO PURCHASE SHARES OF COMMON STOCK of BOLT BIOTHERAPEUTICS, INC. Dated as of July 26, 2018 Void after the date specified in Section 8Bolt Biotherapeutics, Inc. • September 11th, 2020 • Pharmaceutical preparations • California
THIS CERTIFIES THAT, in consideration of the sum of $ , , or its registered assigns (the “Holder”), is entitled, subject to the provisions and upon the terms and conditions set forth herein, to purchase from Bolt Biotherapeutics, Inc., a Delaware corporation (the “Company”), shares of the Company’s Common Stock, $0.00001 par value per share (the “Shares”), in the amounts, at such times and at the price per share set forth in Section 1. The term “Warrant” as used herein shall include this Warrant and any warrants delivered in substitution or exchange therefor as provided herein. This Warrant is issued in connection with the transactions described in the Series B Preferred Stock Purchase Agreement, dated as of July 26, 2018, by and among the Company and the purchasers described therein (the “Purchase Agreement”). The holder of this Warrant is subject to certain restrictions set forth in the Purchase Agreement and the Amended and Restated Investors’ Rights Agreement, dated as of July 26,
SUMMARY OF BASIC LEASE INFORMATIONLease • September 11th, 2020 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations • California
BOLT BIOTHERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT June 26, 2020Investors’ Rights Agreement • September 11th, 2020 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 26th day of June, 2020 by and among BOLT BIOTHERAPEUTICS, INC., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
INDEMNITY AGREEMENTIndemnity Agreement • January 15th, 2021 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , is made by and between BOLT BIOTHERAPEUTICS, INC., a Delaware corporation (the “Company” or “Bolt”), and (“Indemnitee”).
AMENDED AND RESTATED SUPPLY AGREEMENTSupply Agreement • May 12th, 2022 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations • New York
This Amended and Restated Supply Agreement (the “Agreement”) is made and entered into as of the date of the last signature hereto (the “Effective Date”) by and between EirGenix, Inc., a Taiwanese corporation having its principal place of business at No. 101, Lane 169, Kangning Street, Xizhi District, New Taipei City 22180, Taiwan (“EirGenix”), and Bolt Biotherapeutics, Inc., a Delaware corporation having its principal place of business at 900 Chesapeake Drive, Redwood City, CA 94063 USA (“Bolt”).
BOLT BIOTHERAPEUTICS, INC. CONSULTING AGREEMENTConsulting Agreement • May 14th, 2024 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations
This Consulting Agreement (“Agreement”) is entered into as of May 13, 2024 and will be effective as of July 15, 2024 (the “Effective Date”) between Bolt Biotherapeutics, Inc. (“Company”) and Randall C. Schatzman, Ph.D. (“Consultant”). Company desires to retain Consultant to perform certain consulting activities as described below, and Consultant desires to serve as a consultant to Company and perform such activities under the terms of this Agreement.
BOLT BIOTHERAPEUTICS, INC. STOCK OPTION AGREEMENTEquity Incentive Plan • February 1st, 2021 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations
As reflected by your Stock Option Grant Notice (“Grant Notice”) Bolt Biotherapeutics, Inc. (the “Company”) has granted you an option under its 2021 Equity Incentive Plan (the “Plan”) to purchase a number of shares of Common Stock at the exercise price indicated in your Grant Notice (the “Option”). Capitalized terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the meanings set forth in the Grant Notice or Plan, as applicable. The terms of your Option as specified in the Grant Notice and this Stock Option Agreement constitute your Option Agreement.
EXCLUSIVE (EQUITY) AGREEMENTOriginal Agreement • January 11th, 2021 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Bolt Therapeutics (“Bolt”), a corporation having a principal place of business at 1556 Rubino Court, Pleasanton, CA 94566, is effective on the 18th day of May, 2015 (“Effective Date”).
January 26, 2017Bolt Biotherapeutics, Inc. • September 11th, 2020 • Pharmaceutical preparations
SUBLEASE AGREEMENTSublease Agreement • January 15th, 2021 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations • California
THIS SUBLEASE AGREEMENT (the “Sublease”) is made and entered into as of the 18th day of April, 2019 by and between ARMO BIOSCIENCES, INC., a Delaware corporation (“Sublandlord”) and BOLT BIOTHERAPEUTICS, INC., a Delaware corporation (“Subtenant”), all with respect to the following:
CONSENT TO SUBLEASE AGREEMENTConsent to Sublease Agreement • January 15th, 2021 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations • California
THIS CONSENT TO SUBLEASE AGREEMENT (this “Agreement”) is made as of June 14, 2019, by and among HCP LS REDWOOD CITY, LLC, a Delaware limited liability company (“Landlord”), ARMO BIOSCIENCES, INC., a Delaware corporation (“Tenant”), and BOLT BIOTHERAPEUTICS, INC., a Delaware corporation (“Subtenant”).
BOLT BIOTHERAPEUTICS, INC. CONSULTING AGREEMENT Effective Date: March 3, 2022Consulting Agreement • March 4th, 2022 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations • Delaware
This Consulting Agreement (the “Agreement”) is made as of the Effective Date set forth above by and between Bolt Biotherapeutics, Inc., a Delaware corporation (“Client”) and the consultant named on the signature page hereto (“Consultant”). The Company and Consultant acknowledge and agree that the Consultant’s last day of employment with the Company will be March 11, 2022 (the “Resignation Date”).
FIRST Amendment to LEASE AGREEMENTLease Agreement • March 29th, 2023 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations
This First Amendment to Lease Agreement (this “First Amendment”) is made as of November 7, 2022 by and between HCP LS REDWOOD CITY, LLC, a Delaware limited liability company (“Landlord”) and BOLT BIOTHERAPEUTICS, INC., a Delaware corporation (“Tenant”).
LEASE BETWEEN METROPOLITAN LIFE INSURANCE COMPANY (LANDLORD) AND BOLT BIOTHERAPEUTICS, INC. (TENANT) SEAPORT CENTRE Redwood City, CaliforniaWorkletter Agreement • September 11th, 2020 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations • California
EXCLUSIVE AGREEMENTExclusive Agreement • January 15th, 2021 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and BOLT BIOTHERAPEUTICS, INC. (“Bolt”), a company having a primary place of business at 640 Galveston Drive, Redwood City, CA 94063, is effective on the 1st day of June, 2018 (“Effective Date”).
MASTER SERVICES AGREEMENTMaster Services Agreement • September 11th, 2020 • Bolt Biotherapeutics, Inc. • Pharmaceutical preparations
This Master Services Agreement (together with all signed Statement(s) of Work and signed Change Orders, the “Agreement”) is made and entered into as of June 26, 2018 (the “Effective Date”) by and between Bolt Biotherapeutics, Inc. (“Bolt”), a Delaware corporation with an office at 640 Galveston Drive, Redwood City, CA 94063, U.S.A., and Piramal Healthcare UK Ltd (“Piramal”), a British corporation, with registered office at Whalton Road, Morpeth, Northumberland, NE613YA, UK. Bolt and Piramal hereinafter may be referred to individually as a “Party” or collectively as the “Parties”.
